ClearPoint Neuro stock (US18507C1099): Q1 revenue surges 43% to $12.1M

ClearPoint Neuro reported Q1 2026 revenue of $12.1 million, up 43% year-over-year, with guidance for $52-56 million full-year sales. The neurotherapy navigation firm also secured CE Marking for its Velocity Alpha MR drill.

ClearPoint Neuro (Nasdaq: CLPT) posted first-quarter 2026 revenue of $12.1 million, a 43% increase from $8.5 million in the prior-year period, according to its 8-K filing as of May 13, 2026. Organic revenue grew 16%, driven by 25% higher device sales and contributions from the IRRAflow acquisition. The company guided for full-year 2026 revenue of $52-56 million, implying continued expansion in neurosurgery navigation and drug delivery.

Separately, ClearPoint Neuro announced CE Marking approval for its Velocity Alpha MR High Speed Surgical Drill System on May 13, 2026, expanding its European footprint after prior US FDA clearance, per the company press release as of May 13, 2026. This supports the firm's ecosystem for precise brain and spine interventions.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: ClearPoint Neuro, Inc.
• Sector/industry: Medical Devices - Neurosurgery Navigation
• Headquarters/country: Solana Beach, CA / United States
• Core markets: US, Europe, Asia-Pacific
• Key revenue drivers: Navigation systems, drug delivery services, IRRAflow
• Home exchange/listing venue: Nasdaq (CLPT)
• Trading currency: USD

ClearPoint Neuro: core business model

ClearPoint Neuro develops integrated systems for minimally invasive neurosurgical procedures, enabling precise navigation to the brain and spine. The platform supports device, cell, and gene therapies with real-time MRI guidance. Neurosurgery navigation, therapy, and access revenue jumped 80% to $5.9 million in Q1 2026 from the year-ago quarter, per the 8-K filing as of May 13, 2026.

Capital equipment and software sales soared 177% to $1.4 million, reflecting equipment placements and recurring software revenue. The company serves over 60 active biopharma partners and has expanded via the IRRAflow neurocritical care acquisition.

Main revenue and product drivers for ClearPoint Neuro

Key drivers include the ClearPoint Neuro Navigation System, biologics drug delivery services, and the IRRAflow platform for intracranial fluid management. Q1 gross margin improved to 64% from 60%, supported by higher-margin devices and services. Full-year guidance of $52-56 million anticipates scaling across these segments, up from $37 million in 2025.

Recent milestones include FDA clearance and now CE Marking for Velocity Alpha MR, Health Canada approval for navigation, and the first commercial drug delivery case in Asia-Pacific, as noted in the Q1 report.

Industry trends and competitive position

The neurotechnology sector benefits from rising demand for precision therapies in oncology, gene editing, and neurodegenerative diseases. ClearPoint Neuro's MRI-compatible systems differentiate it in cell and gene delivery, with growing adoption by pharma partners. US investors gain exposure to this high-growth medtech niche via the Nasdaq listing.

Conclusion

ClearPoint Neuro's Q1 results highlight robust demand for its navigation and therapy platforms, with 43% revenue growth and expanded international approvals positioning it for full-year guidance achievement. Operating expenses rose amid acquisition integration, but margin gains signal operational leverage. US investors track the firm's progress in neurotherapy innovation amid a dynamic medtech landscape.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.